← 返回

BTN3A:癌症预后和治疗中一个有前景的免疫检查点

英文原题:BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.

查看英文原题

BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and Treatment.

PubMed 2022/11/03(内容时间) Int J Mol Sci Q1 · IF 5.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Butyrophilin-3A (BTN3A) 亚家族成员是一组存在于不同细胞类型表面的免疫球蛋白,包括先天免疫细胞和癌细胞。由于它们与 B7 家族成员高度相似,已有不同研究开展并揭示了 BTN3A 分子参与调节肿瘤微环境 (TME) 中 T 细胞活性。然而,这些研究的很大一部分集中在 γδ T 细胞以及 BTN3A 如何促进其功能上。在这篇综述中,我们将描述 BTN3A 分子在不同肿瘤微环境中的作用和各个方面,并回顾 BTN3A 受体如何调节多种免疫效应功能,包括 CD4+ (Th1)、细胞毒性 CD8+ T 细胞和 NK 细胞的功能。我们还将强调 BTN3A 分子作为有效免疫治疗和成功控制癌症的治疗靶点的潜力,这可能代表患者治疗的光明未来。

展开英文摘要原文

Butyrophilin-3A (BTN3A) subfamily members are a group of immunoglobulins present on the surface of different cell types, including innate and cancer cells. Due to their high similarity with the B7 family members, different studies have been conducted and revealed the involvement of BTN3A molecules in modulating T cell activity within the tumor microenvironment (TME).

However, a great part of this research focused on γδ T cells and how BTN3A contributes to their functions. In this review, we will depict the roles and various aspects of BTN3A molecules in distinct tumor microenvironments and review how BTN3A receptors modulate diverse immune effector functions including those of CD4+ (Th1), cytotoxic CD8+ T cells, and NK cells.

We will also highlight the potential of BTN3A molecules as therapeutic targets for effective immunotherapy and successful cancer control, which could represent a bright future for patient treatment.

论文信息

作者
Kone AS、Ait Ssi S、Sahraoui S、Badou A
单位
Laboratory of Immuno-Genetics and Human Pathologies, Faculty of Medicine and Pharmacy of Casablanca, Hassan II University, Casablanca 20000, Morocco.Morocco
文献类型
综述
期刊
International journal of molecular sciences2022 Nov 3
原文标识
PubMed 36362212 · DOI 10.3390/ijms232113424